Strategic Regulatory Implementation Services
Senior Manager | Risk and Financial Advisory
555 12th St. NW
Daniel is one of the leaders of Deloitte’s Strategic Regulatory Implementation Services offering. Building off of more than 18 years of experience in health care professional services, Daniel works with health care providers, health plans, medical technology companies, investors and other stakeholders to identify key factors that will drive changes in the health care marketplace. Daniel regularly speaks and writes on health care regulatory and legislative issues in his role as a key health care contributor to the Deloitte Center for Regulatory Strategies.
Daniel helps lead regulatory strategy engagements with key clients in the health care industry, including large, multi-state health systems, national payers, and other Fortune 100 companies. Daniel works with stakeholders to evaluate and plan for strategic opportunities and risks based on analysis of government and private sector data; market trends; and political, legislative and regulatory issues affecting the health care industry.
Daniel also works with Deloitte’s health care Mergers, Acquisitions and Transactions Services team to help clients incorporate key regulatory drivers into their investment theses and evaluate potential targets in light of shifting market dynamics and reimbursement trends. Daniel regularly presents to major health care private equity investors and is a featured speaker as part of Deloitte’s leadership sessions at the annual J.P. Morgan Health Care Investors Conference.
Prior to joining Deloitte, Daniel spent five years at a global professional services firm advising organizations on the implementation of the Affordable Care Act. Daniel spent his early career at a leading research, technology, and consulting firm focused on the health care industry.
New payment-related Medicare demonstration project begins
CMMI brings risk to Part D, other Medicare Advantage changes
HHS proposes removal of safe harbor protections for prescription drugs